1,008 Shares in argenx SE (NASDAQ:ARGX) Bought by Headlands Technologies LLC

Headlands Technologies LLC acquired a new position in argenx SE (NASDAQ:ARGX) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,008 shares of the company’s stock, valued at approximately $397,000.

Several other institutional investors also recently modified their holdings of the business. GAMMA Investing LLC boosted its position in argenx by 420.0% during the first quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after acquiring an additional 63 shares during the last quarter. Mather Group LLC. bought a new stake in argenx during the first quarter valued at $38,000. FNY Investment Advisers LLC bought a new stake in argenx during the fourth quarter valued at $38,000. Benjamin F. Edwards & Company Inc. bought a new stake in argenx during the fourth quarter valued at $60,000. Finally, Lindbrook Capital LLC boosted its position in argenx by 23.1% during the first quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock valued at $78,000 after acquiring an additional 37 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Stock Down 0.4 %

Shares of NASDAQ ARGX traded down $1.76 during mid-day trading on Wednesday, reaching $470.04. 53,206 shares of the company were exchanged, compared to its average volume of 309,560. argenx SE has a 52 week low of $327.73 and a 52 week high of $550.76. The stock has a market capitalization of $27.93 billion, a PE ratio of -83.20 and a beta of 0.64. The company’s 50 day moving average price is $399.59 and its 200 day moving average price is $390.35.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Monday, May 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.33). argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. The company had revenue of $412.51 million for the quarter, compared to the consensus estimate of $404.03 million. During the same period in the prior year, the firm posted ($0.52) earnings per share. On average, sell-side analysts predict that argenx SE will post -2.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on ARGX shares. Evercore ISI upped their price target on shares of argenx from $478.00 to $533.00 and gave the company an “outperform” rating in a research report on Friday, July 12th. HC Wainwright restated a “buy” rating and issued a $448.00 target price on shares of argenx in a research note on Monday, June 24th. Bank of America reaffirmed a “buy” rating and issued a $607.00 price target (up previously from $535.00) on shares of argenx in a research report on Monday, June 24th. Wells Fargo & Company raised their price target on shares of argenx from $478.00 to $542.00 and gave the company an “overweight” rating in a research report on Monday, June 24th. Finally, Morgan Stanley dropped their price target on shares of argenx from $515.00 to $510.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 28th. Five equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, argenx presently has an average rating of “Moderate Buy” and a consensus target price of $530.53.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.